Keyphrases
Metastatic Colorectal Cancer (mCRC)
100%
Overall Survival
79%
Confidence Interval
63%
Stage III Colon Cancer
40%
ST-elevation Myocardial Infarction (STEMI)
40%
Progression-free Survival
40%
Crusades
38%
National Cardiovascular Data Registry
37%
Percutaneous Coronary Intervention
36%
Acute Coronary Syndrome
33%
Hazard Ratio
32%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
31%
Bevacizumab
31%
Cetuximab
31%
Leukemia
29%
Colorectal Cancer
25%
Tumor
23%
Disease-free Survival
22%
Odds Ratio
22%
Phase II Trial
20%
Quality Improvement Initiatives
20%
Chemotherapy
19%
Advanced Colorectal Cancer
17%
Clinical Trials
17%
In Cancer
16%
Acute Myocardial Infarction
16%
In-hospital Mortality
16%
Oxaliplatin
16%
Colon Cancer
16%
Patients with Colorectal Cancer
15%
Primary Percutaneous Coronary Intervention
15%
Cancer Recurrence
14%
Randomized Clinical Trial
14%
Adverse Outcomes
14%
Clopidogrel
14%
Adjusted Odds Ratio
14%
Risk Stratification
13%
Advanced or Metastatic
13%
Adjuvant Chemotherapy
12%
Quality of Care
12%
Cancer Mortality
12%
Clinical Outcomes
12%
Irinotecan
12%
American Heart Association Guidelines
12%
Stable Angina
12%
Early Implementation
12%
Coronary Artery Bypass Graft Surgery
11%
Gene Expression
11%
5-fluorouracil (5-FU)
11%
In-hospital Outcomes
11%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
81%
Overall Survival
80%
Progression Free Survival
51%
Colorectal Carcinoma
43%
Acute Coronary Syndrome
43%
Malignant Neoplasm
41%
Neoplasm
40%
Bevacizumab
30%
Cetuximab
29%
Chemotherapy
29%
Clinical Trial
26%
Colon Carcinoma
26%
Leukemia
24%
ST Segment Elevation Myocardial Infarction
19%
Diseases
19%
Biological Marker
16%
Heart Infarction
14%
Adverse Event
14%
Cerebrovascular Accident
13%
Randomized Clinical Trial
13%
Disease Free Survival
13%
Acute Heart Infarction
10%
Hospital Mortality
10%
Clopidogrel
9%
Epidermal Growth Factor Receptor
9%
All Cause Mortality
9%
Phase II Trials
9%
First-Line Chemotherapy
8%
Bleeding
8%
Bile Duct Carcinoma
8%
Dietary Fat
8%
Circulating Tumor DNA
8%
Phase III Trials
8%
Cardiogenic Shock
8%
Oxaliplatin
8%
Cohort Study
8%
Adverse Outcome
7%
Placebo
7%
Capecitabine
7%
Regorafenib
7%
Comorbidity
7%
Disease Exacerbation
7%
Recurrent Disease
6%
Pancreas Islet Cell Tumor
6%
Unstable Angina Pectoris
6%
Fibrinogen Receptor
6%
Acetylsalicylic Acid
6%
Non ST Segment Elevation Myocardial Infarction
6%
Molecular Marker
5%
Irinotecan
5%
Medicine and Dentistry
Overall Survival
43%
Acute Coronary Syndrome
39%
Colon Carcinoma
39%
Metastatic Colorectal Cancer
38%
Cardiovascular System
37%
Colorectal Carcinoma
29%
Hazard Ratio
29%
Odds Ratio
26%
Progression Free Survival
26%
ST Elevation
26%
Malignant Neoplasm
26%
Percutaneous Coronary Intervention
24%
Neoplasm
23%
ST Segment Elevation Myocardial Infarction
21%
Quality Improvement
19%
Leukemia
18%
Disease Free Survival
15%
Myocardial Infarction
15%
Non ST Segment Elevation Myocardial Infarction
15%
Diseases
13%
Phase II Trials
13%
Coronary Artery Bypass Graft Surgery
13%
Oxaliplatin
12%
Gene Expression
12%
Apoplexy
12%
Cetuximab
12%
Bevacizumab
11%
Recurrent Disease
11%
Adjuvant Chemotherapy
11%
Acute Heart Infarction
10%
Capecitabine
10%
Biological Marker
10%
Bleeding
9%
Arm
9%
Cancer Recurrence
9%
Randomized Clinical Trial
9%
Primary Percutaneous Coronary Intervention
9%
Oncology
9%
Randomized Controlled Trial
8%
Adverse Outcome
8%
Clinical Trial
8%
Circulating Tumor DNA
8%
Cholangiocarcinoma
8%
Protocol Compliance
8%
Distal Radius
8%
Thrombocytopenia
8%
Recurrence Free Survival
8%
Congestive Heart Failure
7%
Tumor Infiltrating Lymphocyte
7%
Coronary Artery Disease
7%